Ghayas Issa, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the value of understanding the genomic composition of acute myeloid leukemia (AML) and explains how whole genome and next-generation sequencing (WGS; NGS) could be used to tailor treatments in the future. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.